Benzinga’s Top Ratings Upgrades, Downgrades For April 28, 2023
Upgrades Deutsche Bank upgraded the previous rating for Old Dominion Freight Line Inc (NASDAQ:ODFL) from Hold to Buy.…
Benzinga’s Top Ratings Upgrades, Downgrades For April 27, 2023
Upgrades According to Huber Research, the prior rating for Meta Platforms Inc (NASDAQ:META) was changed from Neutral to…
Credit Where It’s Due: TransUnion Gets A ‘Buy’ Upgrade As Q1 Results Crush Expectations
Needham analyst Kyle Peterson upgraded the rating on TransUnion (NYSE:TRU) to Buy from Hold at a price target of $84. The analyst…
Navigating Natural Gas: Range Resources Impresses with Q1 Earnings, Attracts Analyst Upgrades
Range Resources Corp (NYSE:RRC) is gaining analysts’ confidence post reporting strong Q1 2023 results yesterday. Benchmark Company analyst Subash Chandra upgraded…
This Analyst Turns Bullish On Healthpeak Properties, Sees Growth Prospect From Strong Tenant Base
Mizuho Securities analyst Vikram Malhotra upgraded Healthpeak Properties Inc (NYSE:PEAK) to Buy from Neutral and decreased the price target to $25 from…
Benzinga’s Top Ratings Upgrades, Downgrades For April 24, 2023
Upgrades For Medtronic PLC (NYSE:MDT), Barclays upgraded the previous rating of Equal-Weight to Overweight. Medtronic earned $1.30 in…
Benzinga’s Top Ratings Upgrades, Downgrades For April 21, 2023
Upgrades Argus Research upgraded the previous rating for Dollar General Corp (NYSE:DG) from Hold to Buy. For the…
Capri Will See EPS Beats In Future, Confident Analyst Upgrades Stock To Strong Buy
Raymond James analyst Rick B. Patel upgraded Capri Holdings Ltd (NYSE:CPRI) to Strong Buy from Outperform at a price target of $60.…
Benzinga’s Top Ratings Upgrades, Downgrades For April 20, 2023
Upgrades Jefferies upgraded the previous rating for Relay Therapeutics Inc (NASDAQ:RLAY) from Underperform to Hold. For the fourth…
Analyst Doubles Immuneering Price Target Citing Initial Data Validation
Tuesday, Immuneering Corporation (NASDAQ:IMRX) announced initial pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the Phase 1 trial of IMM-1-104. IMM-1-104…